Overview
Patients undergoing elective abdominal surgery will be included prospectively. Informed consent will be obtained. Preoperatively baseline health data is collected and a skin swab and rectal swab for baseline skin and gut microbiota is taken. During the surgery additional clinical data and additional samples will be obtained. Additional samples include: rectal swab, biopsies of the resected specimen (lymph node, peritoneum, intestinal content, mucosa), venous blood sample (7.5ml) at the end of the operation, liver biopsy and skin biopsy. Postoperative health data is recorded. If a surgical site infection occurs a swab is taken too. With 16 sRNA (small ribonucleic acid) based sequencing the investigators will quantify the abundance of the different bacterial species in all samples. Primary outcome will be to assess a difference of 16sRNA signal in the liver and lymph node biopsies between patients with and patients without surgical site infection. Secondary outcomes include variables predicting the occurence of surgical site infections and a model describing the way bacteria may take to cause wound infection.
Eligibility
Inclusion Criteria:
- Informed Consent
- All Ages
- All Gender
- Elective Abdominal Surgery
- Age > 18
- All approached (laparoscopic, open)
- All ethnic and sociodemographic backgrounds
- Sufficient knowledge of the study language (German)
Exclusion Criteria:
- pregnant or lactating women
- no operation performed (i.e. only planned)
- insufficient knowledge of project language (German)
- lack of informed consent
- known colonization with multi-resistant bacteria (e.g. Methicillin-resistant Staphylococcus aureus (MRSA) or extended spectrum betalactamase (ESBL))
- known cirrhotic liver disease